JP4291412B2 - リポソーマルホスホジエステル、ホスホロチオエート、およびｐ−エトキシオリゴヌクレオチド - Google Patents

リポソーマルホスホジエステル、ホスホロチオエート、およびｐ−エトキシオリゴヌクレオチド Download PDF

Info

Publication number
JP4291412B2
JP4291412B2 JP51064297A JP51064297A JP4291412B2 JP 4291412 B2 JP4291412 B2 JP 4291412B2 JP 51064297 A JP51064297 A JP 51064297A JP 51064297 A JP51064297 A JP 51064297A JP 4291412 B2 JP4291412 B2 JP 4291412B2
Authority
JP
Japan
Prior art keywords
liposome
oligonucleotide
antisense
oligo
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51064297A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512099A (ja
JPH11512099A5 (OSRAM
Inventor
ベレスタイン ガブリエル ロペス
アナ マリア タリ
Original Assignee
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム filed Critical ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Publication of JPH11512099A publication Critical patent/JPH11512099A/ja
Publication of JPH11512099A5 publication Critical patent/JPH11512099A5/ja
Application granted granted Critical
Publication of JP4291412B2 publication Critical patent/JP4291412B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicon Polymers (AREA)
JP51064297A 1995-08-29 1996-08-26 リポソーマルホスホジエステル、ホスホロチオエート、およびｐ−エトキシオリゴヌクレオチド Expired - Fee Related JP4291412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/520,385 1995-08-29
US08/520,385 US5855911A (en) 1995-08-29 1995-08-29 Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
PCT/US1996/014146 WO1997007784A2 (en) 1995-08-29 1996-08-26 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES

Publications (3)

Publication Number Publication Date
JPH11512099A JPH11512099A (ja) 1999-10-19
JPH11512099A5 JPH11512099A5 (OSRAM) 2004-09-09
JP4291412B2 true JP4291412B2 (ja) 2009-07-08

Family

ID=24072378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51064297A Expired - Fee Related JP4291412B2 (ja) 1995-08-29 1996-08-26 リポソーマルホスホジエステル、ホスホロチオエート、およびｐ−エトキシオリゴヌクレオチド

Country Status (11)

Country Link
US (4) US5855911A (OSRAM)
EP (1) EP0847272B1 (OSRAM)
JP (1) JP4291412B2 (OSRAM)
AT (1) ATE253897T1 (OSRAM)
AU (1) AU6912996A (OSRAM)
CA (1) CA2228944C (OSRAM)
DE (1) DE69630691T2 (OSRAM)
DK (1) DK0847272T3 (OSRAM)
ES (1) ES2210385T3 (OSRAM)
PT (1) PT847272E (OSRAM)
WO (1) WO1997007784A2 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6894031B1 (en) * 1996-11-21 2005-05-17 Cedars-Sinai Medical Center Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1017365B1 (en) * 1997-06-23 2003-12-10 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
JP2002510319A (ja) * 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP1163254B1 (en) 1999-02-26 2008-01-30 The University of British Columbia Trpm-2 antisense therapy
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ524274A (en) 2000-09-14 2004-10-29 Univ British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
WO2003061386A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer
DE60322509D1 (de) * 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
KR101052289B1 (ko) 2002-08-21 2011-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 클러스테린 양의 감소에 의한 흑색종의 치료
DE60332363D1 (de) 2002-10-02 2010-06-10 Univ British Columbia Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
CA2520864A1 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
WO2005018493A1 (en) 2003-08-14 2005-03-03 Boston Scientific Limited Medical slings
EP1667731B1 (en) * 2003-10-01 2013-05-22 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US20050112130A1 (en) 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
JP2007512355A (ja) 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US8628465B2 (en) * 2004-06-14 2014-01-14 Boston Scientific Scimed, Inc. Systems, methods and devices relating to implantable supportive slings
EP1814913B1 (en) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antibody induced cell membrane wounding
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
US8016741B2 (en) * 2005-04-06 2011-09-13 Boston Scientific Scimed, Inc. Systems, devices, and methods for sub-urethral support
JP2008536874A (ja) * 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
WO2007008209A1 (en) 2005-07-13 2007-01-18 Boston Scientific Scimed Inc. Snap fit sling anchor system and related methods
EP3533416A1 (en) 2005-07-25 2019-09-04 Boston Scientific Limited Pelvic floor repair system
US7981023B2 (en) * 2005-07-25 2011-07-19 Boston Scientific Scimed, Inc. Elastic sling system and related methods
US8273429B2 (en) * 2006-01-19 2012-09-25 Federal-Mogul World Wide, Inc. Fabric for end fray resistance and protective sleeves formed therewith and methods of construction
FR2900576B1 (fr) 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
WO2008106781A1 (en) * 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
EP2306978A2 (en) * 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of rnai agents
ES2710109T3 (es) 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Acidos nucleicos que se dirigen a TCTP para su uso en el tratamiento de cánceres quimiorresistentes u hormonorresistentes
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
US9113991B2 (en) 2011-05-12 2015-08-25 Boston Scientific Scimed, Inc. Anchors for bodily implants and methods for anchoring bodily implants into a patient's body
US9636201B2 (en) 2011-05-12 2017-05-02 Boston Scientific Scimed, Inc. Delivery members for delivering an implant into a body of a patient
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014195755A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a ketal group
WO2014195754A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
EA038277B1 (ru) * 2015-10-14 2021-08-04 Байо-Пат Холдингз, Инк. P-этокси нуклеиновые кислоты для липосомальной лекарственной формы
CN108601765A (zh) 2015-12-18 2018-09-28 德克萨斯州大学系统董事会 用于早产管理的治疗剂
SG10201913501RA (en) * 2016-09-14 2020-03-30 Univ Nanyang Tech Liposomal formulations
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
SG11201903283UA (en) 2016-10-12 2019-05-30 Univ Texas Methods and compositions for tusc2 immunotherapy
WO2018195250A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
SG11201909336VA (en) 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
AU2018254485B2 (en) * 2017-04-19 2024-07-11 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for IGF-1R inhibition
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
IL297450A (en) 2020-04-20 2022-12-01 Univ Texas Compositions of biologically active dry powder, methods for production and use
WO2022040435A1 (en) 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (OSRAM) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5094785A (en) * 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
FR2644080A1 (fr) * 1989-03-13 1990-09-14 Trizac Jacques Dispositif de filtration et d'evacuation de petites particules, dechets et detritus, de natures diverses
AU639925B2 (en) * 1989-04-18 1993-08-12 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
US5112962A (en) * 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991016901A1 (en) * 1990-04-30 1991-11-14 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
DK0464638T3 (da) * 1990-07-02 1997-10-13 Hoechst Ag Oligonukleotidanaloge med terminale 3-3- eller 5-5-internukleotidbindinger.
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JPH06501160A (ja) * 1990-09-17 1994-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞の増殖をコントロールするための方法及び組成物
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
DE4110085A1 (de) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
AU2916292A (en) * 1991-10-24 1993-05-21 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
AU675923B2 (en) * 1991-12-04 1997-02-27 E.I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
NL9201440A (nl) * 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
WO1994005259A1 (en) * 1992-09-02 1994-03-17 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
DE69330137T2 (de) 1992-10-21 2001-11-15 Temple University Of The Commonwealth System Of Higher Education, Philadelphia Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
AU683957B2 (en) * 1993-11-05 1997-11-27 Amgen, Inc. Liposome preparation and material encapsulation method
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
IT1275862B1 (it) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
ES2268705T3 (es) * 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
US6326487B1 (en) * 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
CA2222328C (en) * 1995-06-07 2012-01-10 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0843555B1 (en) * 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5874224A (en) * 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
EP1017365B1 (en) * 1997-06-23 2003-12-10 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6136965A (en) * 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Also Published As

Publication number Publication date
WO1997007784A2 (en) 1997-03-06
CA2228944A1 (en) 1997-03-06
AU6912996A (en) 1997-03-19
US20070202157A1 (en) 2007-08-30
ES2210385T3 (es) 2004-07-01
US5855911A (en) 1999-01-05
PT847272E (pt) 2004-04-30
ATE253897T1 (de) 2003-11-15
US7754872B2 (en) 2010-07-13
DE69630691T2 (de) 2004-11-25
JPH11512099A (ja) 1999-10-19
EP0847272A2 (en) 1998-06-17
EP0847272B1 (en) 2003-11-12
US20040005353A1 (en) 2004-01-08
DE69630691D1 (de) 2003-12-18
DK0847272T3 (da) 2004-03-22
US7176302B2 (en) 2007-02-13
WO1997007784A3 (en) 1997-04-24
CA2228944C (en) 2011-10-18
US6042846A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
JP4291412B2 (ja) リポソーマルホスホジエステル、ホスホロチオエート、およびｐ−エトキシオリゴヌクレオチド
EP0711149B1 (en) Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
Weissig et al. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems
AU2009330859B2 (en) Pharmaceutical composition containing an anionic drug, and a production method therefor
US20100285111A1 (en) Self-assembling micelle-like nanoparticles for systemic gene delivery
US9532950B2 (en) Vector for pulmonary delivery, inducing agent, and uses
KR19990036033A (ko) 리포소옴성 올리고뉴클레오티드 조성물
Weissig et al. Mitochondriotropic cationic vesicles a strategy towards mitochondrial gene therapy
US7262173B2 (en) Chemosensitizing with liposomes containing oligonucleotides
JP5382682B2 (ja) 薬物送達複合体
Zhou et al. Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids
KR101678327B1 (ko) 약산성 pH 응답성 펩티드 및 상기 펩티드를 포함하는 리포솜
Zelphati et al. Cationic liposomes as an oligonucleotide carrier: mechanism of action
Tari et al. Oligonucleotide therapy for hematological malignancies
Woodle et al. Liposomal antisense oligonucleotide therapeutics
HK1016409B (en) Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
HK1154053A (en) Self-assembling micelle-like nanoparticles for systemic gene delivery
HK1025906A1 (en) Liposome-entrapped polynucleotide composition and method
HK1025906B (en) Liposome-entrapped polynucleotide composition and method

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090403

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120410

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120410

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130410

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140410

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees